跳至主要内容
临床试验/NCT01383395
NCT01383395已完成1 期

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects

Samsung Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
1
主要终点
Plasma concentration of simvastatin

研究概览

简要总结

To evaluate the effect of cilostazol on the pharmacokinetics of simvastatin in healthy adult subjects.

详细描述

Eligibility for participation of this study was determined from demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 4 weeks before study drug administration. Subjects suitable for this study were admitted to the Clinical Trials Center, Samsung Medical Center on the day before dosing, and they were overnight-fasted from 10 p.m. of Day -1. Subjects were dosed simvastatin 40 mg orally around at 9 a.m. of Day 1. Subjects performed scheduled procedures including clinical laboratory tests and pharmacokinetic samplings for simvastatin. Subjects were dosed cilostazol 100 mg in the morning on Day 2 and discharged, and visited Clinical Trials Center on Day 3, Day 4 and Day 5 for the oral administration of cilostazol 100 mg. Subjects was admitted in the evening on day 5 and dosed simvastatin 40 mg plus cilostazol 100 mg concomitantly and scheduled pharmacokinetic sampling for simvastatin was performed. Next morning (Day 7), subjects were discharged

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 48 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male subjects aged 20 - 48 years
  • A body mass index (BMI) in the range 19-27 kg/m2
  • Provide written informed consent after being fully informed about the study procedures
  • Subject without any congenital or chronic disease and with no pathologic symptom in the physical examination
  • Determined eligible in the ECG, clinical laboratory tests and urinalysis

排除标准

  • Use of medication which induces or inhibits drug metabolizing enzyme (CYP3A4 etc.) within 30 days prior to drug dosing
  • Use of medication within 10 days before first dose
  • Abnormal diet that can influence on tlhe ADME of drugs (grapefruit juice etc.)
  • Presence or history of clinically significant allergic disease, alcohol abuse, drug hypersensitivity
  • Whole blood donation during 60 days before the study
  • Participation in other clinical trial within 90 days prior to scheduled study drug administration
  • Subject judged not eligible for study participation by investigator

研究组 & 干预措施

simvastatin/cilostazol

Experimental

simvastatin 40 mg on day 1 and 6, cilostazol 100 mg from day 2 to day 6

干预措施: simvastatin/cilostazol (Drug)

结局指标

主要结局

Plasma concentration of simvastatin

时间窗: 7 days

Plasma concentration of simvastin on day 1 and day 6

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Effect of Cilostazol on the Pharmacokinetics of... | 临床试验